MedTrace Logo

Study of CMV in Kidney Transplant Recipients

NCT02061215 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2024-10-17

No results posted yet for this study

Summary

Using novel CYTOF technology to measure a wide array of innate and adaptive cell proportions and cytokine levels, we plan a pilot study in old (\>/=60 years) and young (20-40 years) renal transplant recipients who are cytomegalovirus (CMV) seropositive (regardless of donor serology). Viral load measurements will be performed at baseline prior to transplant (within 1 week),and then at 3, 7 and 10 months after transplant. It is expected that the patient will receive anti-CMV prophylaxis until 6 months post-transplant, so the latter two time points will reflect responses after "release" from antiviral suppression. Each patient will serve as their own control, with comparisons made between measurements at baseline and then at each timepoint. In addition, clinical data will be collected at the time points indicated, particularly renal function and the presence/absence of acute rejection.

Conditions

  • CMV Viral Loads in Seropositive Renal Transplant Recipients

Interventions

OTHER

CMV viral load

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Alexander Maskin, MD · University of Nebraska

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-07-14
Completion
2015-07-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02061215 on ClinicalTrials.gov